Should I buy or sell Fulcrum Therapeutics stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fulcrum Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" FULC shares. View FULC analyst ratings or view top-rated stocks .

What is Fulcrum Therapeutics' stock price target for 2024?

6 Wall Street research analysts have issued 1 year price objectives for Fulcrum Therapeutics' shares. Their FULC share price targets range from $6.00 to $17.00. On average, they predict the company's share price to reach $13.17 in the next year. This suggests a possible upside of 86.5% from the stock's current price. View analysts price targets for FULC or view top-rated stocks among Wall Street analysts .

How have FULC shares performed in 2024?

Fulcrum Therapeutics' stock was trading at $6.75 at the start of the year. Since then, FULC stock has increased by 4.6% and is now trading at $7.06. View the best growth stocks for 2024 here .

Are investors shorting Fulcrum Therapeutics?

Fulcrum Therapeutics saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 2,260,000 shares, a decrease of 5.4% from the March 15th total of 2,390,000 shares. Based on an average trading volume of 668,800 shares, the days-to-cover ratio is presently 3.4 days. View Fulcrum Therapeutics' Short Interest .

When is Fulcrum Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our FULC earnings forecast .

How were Fulcrum Therapeutics' earnings last quarter?

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) announced its quarterly earnings results on Tuesday, February, 27th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.44) by $0.04. The business earned $0.87 million during the quarter, compared to the consensus estimate of $0.65 million. Fulcrum Therapeutics had a negative trailing twelve-month return on equity of 36.65% and a negative net margin of 3,470.05%.

What ETFs hold Fulcrum Therapeutics' stock?

ETFs with the largest weight of Fulcrum Therapeutics (NASDAQ:FULC) stock in their portfolio include Simplify Propel Opportunities ETF (SURI) , Simplify Health Care ETF (PINK) and SPDR S&P Pharmaceuticals ETF (XPH) . Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) .

What other stocks do shareholders of Fulcrum Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fulcrum Therapeutics investors own include VIVUS (VVUS) , Provention Bio (PRVB) , Entasis Therapeutics (ETTX) , Kaleido Biosciences (KLDO) , VBI Vaccines (VBIV) , Xeris Biopharma (XERS) , CymaBay Therapeutics (CBAY) , Evelo Biosciences (EVLO) and Akero Therapeutics (AKRO) .

When did Fulcrum Therapeutics IPO?

Fulcrum Therapeutics (FULC) raised $76 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 4,500,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and SVB Leerink acted as the underwriters for the IPO.

Who are Fulcrum Therapeutics' major shareholders?

Fulcrum Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Mass General Brigham Inc (0.33%). Insiders that own company stock include Christopher Morabito , Curtis Gale Oltmans , Greg Tourangeau, James A Geraghty , Peter G Thomson , Ra Capital Management, LP, Robert J Gould and Robert J Gould . View institutional ownership trends .

How do I buy shares of Fulcrum Therapeutics?

Shares of FULC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:FULC

Fulcrum Therapeutics (FULC) Stock Price, News & Analysis

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

Free FULC Stock Alerts

$7.06

-0.09 (-1.26%)

(As of 04/18/2024 ET)

Compare

Today's Range: $6.90
▼
$7.21
50-Day Range: $7.15
▼
$12.00
52-Week Range: $2.43
▼
$13.70

Volume: 526,289 shs
Average Volume: 654,179 shs
Market Capitalization: $437.30 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.17

Get Fulcrum Therapeutics alerts:

Fulcrum Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.83 Rating Score
Upside/Downside: 86.5% Upside
$13.17 Price Target
Short Interest: Healthy
3.65% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.83
Based on 3 Articles This Week
Insider Trading: Selling Shares
$57,240 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.76) to ($1.74) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.99 out of 5 stars

Medical Sector

355th out of 919 stocks

Pharmaceutical Preparations Industry

151st out of 406 stocks

3.4

Analyst's Opinion

Consensus Rating
Fulcrum Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Fulcrum Therapeutics has only been the subject of 4 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
3.65% of the outstanding shares of Fulcrum Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Fulcrum Therapeutics has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Fulcrum Therapeutics has recently decreased by 5.44%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Fulcrum Therapeutics does not currently pay a dividend.
Dividend Growth
Fulcrum Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for FULC.

2.1

News and Social Media Coverage

News Sentiment
Fulcrum Therapeutics has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Fulcrum Therapeutics this week, compared to 3 articles on an average week.
Search Interest
Only 6 people have searched for FULC on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Fulcrum Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -90% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Fulcrum Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $57,240.00 in company stock.
Percentage Held by Insiders
Only 2.50% of the stock of Fulcrum Therapeutics is held by insiders.
Percentage Held by Institutions
89.83% of the stock of Fulcrum Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Fulcrum Therapeutics are expected to grow in the coming year, from ($1.76) to ($1.74) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Fulcrum Therapeutics is -4.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Fulcrum Therapeutics is -4.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Fulcrum Therapeutics has a P/B Ratio of 1.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About Fulcrum Therapeutics Stock (NASDAQ:FULC)

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

FULC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

FULC Stock News Headlines

April 15, 2024 | investorplace.com

Biotech on a Budget: 7 Stocks Under $10 With Huge Potential

April 9, 2024 | americanbankingnews.com

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Average Recommendation of "Moderate Buy" by Brokerages

April 18, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

March 28, 2024 | finance.yahoo.com

Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium

March 22, 2024 | globenewswire.com

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 19, 2024 | finance.yahoo.com

FULC Apr 2024 9.000 put

March 19, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT), Fulcrum Therapeutics (FULC) and AC Immune SA (ACIU)

March 18, 2024 | finanznachrichten.de

Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer

April 18, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

March 18, 2024 | msn.com

Fulcrum Therapeutics appoints Patrick Horn as permanent Chief Medical Officer

March 18, 2024 | globenewswire.com

Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer

March 13, 2024 | tmcnet.com

Fulcrum Deepens Collaboration with Esri, Recognized as Bronze Partner

March 8, 2024 | globenewswire.com

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 8, 2024 | msn.com

Fulcrum hits 52-week high as CEO buys shares

March 7, 2024 | finance.yahoo.com

FULC Jun 2024 15.000 call

March 7, 2024 | finance.yahoo.com

CEO, President & Director of Fulcrum Therapeutics Alexander Sapir Buys More Stock

March 5, 2024 | finance.yahoo.com

Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference

March 1, 2024 | markets.businessinsider.com

Strong Buy Rating for Fulcrum Therapeutics Amidst Promising Clinical Progress and Financial Stability

February 29, 2024 | seekingalpha.com

Fulcrum Therapeutics, Inc. (FULC) Q4 2023 Earnings Call Transcript

February 28, 2024 | markets.businessinsider.com

Deep Dive Into Fulcrum Therapeutics Stock: Analyst Perspectives (4 Ratings)

February 28, 2024 | finance.yahoo.com

Fulcrum Therapeutics Full Year 2023 Earnings: Beats Expectations

February 28, 2024 | finance.yahoo.com

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2023 Earnings Call Transcript

February 27, 2024 | globenewswire.com

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023

February 26, 2024 | benzinga.com

Earnings Preview: Fulcrum Therapeutics

February 26, 2024 | markets.businessinsider.com

Fulcrum Therapeutics is about to announce its earnings — here's what to expect

February 22, 2024 | benzinga.com

Fulcrum Therapeutics Stock (NASDAQ:FULC), Short Interest Report

February 20, 2024 | finance.yahoo.com

Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ET

See More Headlines

Receive FULC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fulcrum Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/27/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:FULC
CUSIP: N/A
CIK: 1680581
Web: www.fulcrumtx.com
Phone: (617) 651-8851
Fax: N/A
Employees: 76
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $13.17
High Stock Price Target: $17.00
Low Stock Price Target: $6.00
Potential Upside/Downside: +86.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.83
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.58)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-97,330,000.00
Net Margins: -3,470.05%
Pretax Margin: -3,470.05%
Return on Equity: -36.65%
Return on Assets: -33.62%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 17.71
Quick Ratio: 17.71

Sales & Book Value

Annual Sales: $2.81 million
Price / Sales: 155.62
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.80 per share
Price / Book: 1.86

Miscellaneous

Outstanding Shares: 61,940,000
Free Float: 60,387,000
Market Cap: $437.30 million
Optionable: Optionable
Beta: 2.29

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Mr. Alexander C. Sapir (Age 57)
CEO, President & Director
Dr. Bradley E. Bernstein M.D.
Ph.D., Founder
Dr. Michael R. Green
Founder
Dr. Rudolf Jaenisch M.D.
Ph.D., Founder
Dr. Tsun-Huei Lee M.D. (Age 60)
Ph.D., Founder
Dr. Danny Reinberg
Founder
Mr. Alan A. Musso C.M.A. (Age 62)
CPA, Chief Financial Officer
Mr. Gregory Tourangeau
Controller & Principal Accounting Officer
Dr. Jeffrey W. Jacobs Ph.D. (Age 61)
Chief Scientific Officer
Mr. Curtis G. Oltmans J.D. (Age 61)
Senior VP, Chief Legal Officer & Corporate Secretary
Comp: $83.98k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

FULC Stock Analysis - Frequently Asked Questions

Should I buy or sell Fulcrum Therapeutics stock right now?: 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fulcrum Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" FULC shares.
View FULC analyst ratings or view top-rated stocks.
What is Fulcrum Therapeutics' stock price target for 2024?: 6 Wall Street research analysts have issued 1 year price objectives for Fulcrum Therapeutics' shares. Their FULC share price targets range from $6.00 to $17.00. On average, they predict the company's share price to reach $13.17 in the next year. This suggests a possible upside of 86.5% from the stock's current price.
View analysts price targets for FULC or view top-rated stocks among Wall Street analysts.
How have FULC shares performed in 2024?: Fulcrum Therapeutics' stock was trading at $6.75 at the start of the year. Since then, FULC stock has increased by 4.6% and is now trading at $7.06.
View the best growth stocks for 2024 here.
Are investors shorting Fulcrum Therapeutics?: Fulcrum Therapeutics saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 2,260,000 shares, a decrease of 5.4% from the March 15th total of 2,390,000 shares. Based on an average trading volume of 668,800 shares, the days-to-cover ratio is presently 3.4 days.
View Fulcrum Therapeutics' Short Interest.
When is Fulcrum Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our FULC earnings forecast.
How were Fulcrum Therapeutics' earnings last quarter?: Fulcrum Therapeutics, Inc. (NASDAQ:FULC) announced its quarterly earnings results on Tuesday, February, 27th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.44) by $0.04. The business earned $0.87 million during the quarter, compared to the consensus estimate of $0.65 million. Fulcrum Therapeutics had a negative trailing twelve-month return on equity of 36.65% and a negative net margin of 3,470.05%.

What ETFs hold Fulcrum Therapeutics' stock?: ETFs with the largest weight of Fulcrum Therapeutics (NASDAQ:FULC) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Simplify Health Care ETF (PINK) and SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).
What other stocks do shareholders of Fulcrum Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Fulcrum Therapeutics investors own include VIVUS (VVUS), Provention Bio (PRVB), Entasis Therapeutics (ETTX), Kaleido Biosciences (KLDO), VBI Vaccines (VBIV), Xeris Biopharma (XERS), CymaBay Therapeutics (CBAY), Evelo Biosciences (EVLO) and Akero Therapeutics (AKRO).
When did Fulcrum Therapeutics IPO?: Fulcrum Therapeutics (FULC) raised $76 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 4,500,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and SVB Leerink acted as the underwriters for the IPO.
Who are Fulcrum Therapeutics' major shareholders?: Fulcrum Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Mass General Brigham Inc (0.33%). Insiders that own company stock include Christopher Morabito, Curtis Gale Oltmans, Greg Tourangeau, James A Geraghty, Peter G Thomson, Ra Capital Management, LP, Robert J Gould and Robert J Gould.
View institutional ownership trends.
How do I buy shares of Fulcrum Therapeutics?: Shares of FULC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FULC) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial